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Abstract
Objective—Recent changes in DSM criteria require new documentation of the prevalence and 
developmental sequences of cannabis use disorder. Our goal was to study the early course of 
DSM-5 cannabis use disorder (CUD) and its overlap with DSM-IV and consumption constructs in 
a community-representative sample with American Indians.
Method—Data came from the prospective-longitudinal, population-based Great Smoky 
Mountains Study in North Carolina (N = 1,420, including n = 349 American Indians). Cannabis 
use and disorder were assessed during yearly interviews from ages 9 to 16, and again at ages 19, 
21, 26, and 30 (up to 11 assessments per participant between 1993 and 2015).
Results—By age 30, approximately 70% of participants had used cannabis, 34% had used daily, 
and 18% had met criteria for DSM-5 CUD. Approximately 1 in 4 cannabis users met criteria for 
CUD at some point. Those who met criteria initiated use over two years earlier (at age 13.3) 
compared to other users. Despite higher risks due to increased poverty, American Indians’ patterns 
of use were similar to the rest of the sample. Concordance between DSM-5 CUD and DSM-IV 
abuse/dependence was substantial, but was even higher between DSM-5 CUD and daily use.
Conclusion—It was common to have either used cannabis daily or to have met criteria for 
DSM-5 CUD by adulthood. DSM-5 CUD was an improvement over DSM-IV diagnostic 
constructs by raising the threshold for diagnosis.
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INTRODUCTION
As efforts to legalize and decriminalize cannabis use are growing, cannabis involvement is 
increasingly viewed as harmless by youth (e.g., 1, 2). At the same time, criteria for 
problematic cannabis use were changed with the 2013 transition to DSM-5, and critical 
pieces of information about cannabis disorder and use are currently missing. These include 
basic epidemiological documentation of DSM-5 cannabis use disorder (CUD) prevalence 
and the overlap with DSM-IV diagnostic constructs and frequent-use measures up to age 30.
Several diagnostic changes were implemented with the transition to DSM-5. First, abuse and 
dependence were combined into a single CUD category. Second, a criterion related to 
cannabis-related legal problems was removed. This change may reduce racial/ethnic 
differences in areas in which there are disparities in legal or police contact. Third, a criterion 
related to craving/withdrawal was included. Finally, the threshold to diagnose was increased 
from ≥ 1 criterion to ≥ 2 criteria.3, 4 This last change was implemented to address concerns 
that the threshold for DSM-IV abuse disorder was too low and potentially allowed for 
transient substance problems to be considered diagnostic. These changes in diagnostic 
criteria could impact the overall prevalence of CUD and also who (e.g., in terms of 
frequency of use) is likely to be diagnosed.
The aim of this analysis is to use a community-representative, longitudinal sample of 
children to study DSM-5 CUD from ages 9 to 30. This includes looking at the point 
prevalence of cannabis use at different ages as well as assessing the cumulative prevalence 
of CUD by age 30. Next, we examine the overlap between DSM-5 CUD with DSM-IV 
constructs and different frequency measures of cannabis use (e.g., weekly, daily). One goal 
is to understand whether the DSM changes accomplished what was intended; another is to 
determine how well frequency of cannabis use tracks DSM-5 CUD for clinical diagnostic 
purposes.
American Indians are one of the most understudied segments of the population. The 
longitudinal course of substance use is rarely documented among American Indian youth; 
this gap in research exists, in part, because of a lack of long-term longitudinal studies among 
this group.5,6 On average, substance use among American Indians begins earlier than among 
other races/ethnicities, involves heavier use, and increases more steeply.7,8 Notably, 
considerable tribal and regional variation in use exists. With respect to cannabis use 
specifically, cross-sectional studies—primarily from the Western United States—reported 
that early marijuana use among American Indian youth was common.9 In one tribe, >50% of 
youth had used marijuana by age 13.9 Reasons cited for high cannabis use in this group 
include cultural/historical traditions, easier access to cannabis than to alcohol on some 
reservations,9 and, importantly, demographic hardship— including poverty—endured by 
many American Indians (e.g., 9, 10). The current study examines cannabis use and disorder 
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among American Indian youth from the Cherokee Nation tribe in western North Carolina 
and local residents, who are primarily non-Hispanic whites.
In addition to race/ethnic differences, sex differences in cannabis use and disorder are known 
to exist in adolescence and young adulthood.11–16 More information is needed about when 
such sex differences emerge, and whether sex differences take a similar developmental 
course in American Indian youth compared to other racial/ethnic groups.
METHOD
Participants
The Great Smoky Mountains Study (GSMS) is a prospective, longitudinal study of the 
development of psychiatric disorders and need for mental health services in rural and urban 
youth.17–19 Three cohorts of children aged 9, 11, and 13 years at intake were recruited from 
11 counties in western North Carolina in 1993. The GSMS design and sampling procedures 
are described elsewhere.17,19 Briefly, a two-stage sampling design was employed, which 
oversampled for American Indians, who only make up 3% of the area population but 25% of 
the study sample. Accordingly, all participants were given a weight inversely proportional to 
their probability of selection to create a representative sample of western North Carolina. Of 
all participants recruited, 80% (N=1,420) agreed to participate. Of the 1,420 participants, 
51.1% were female (unweighted n=630), 6.9% were non-Hispanic African-American 
(n=88), and 3.7% were American Indian (n=349). Throughout the results section, 
comparisons are made between the American Indian subsample and the other participants. 
The latter group was labeled “non-Indian” and consisted mainly of non-Hispanic whites and 
the small proportion of non-Hispanic African Americans.
Annual assessments were completed on the 1,420 children until age 16 and then again at 
ages 19, 21, 25, and 30 for a total of 11,084 assessments. The maximum possible number of 
interviews per participant is 8 (oldest cohort), 10 (middle cohort), and 11 (youngest cohort). 
The mean number of interviews to date is 7.7 (SD 2.3). Across all waves, 82.1% of all 
possible interviews were completed, ranging from 74% – 94% at any particular wave.
Procedures
The parent (biological mother for 83% of interviews) and participant were interviewed by 
trained interviewers separately until the participant was 16; thereafter, only participants were 
interviewed. Before the interviews began, both the parent and child signed informed consent 
forms approved by the Duke University Medical Center Institutional Review Board. Each 
parent and child received an honorarium for their participation.
Assessment
All variables were assessed using the Child and Adolescent Psychiatric Assessment (CAPA) 
until age 16, and its upward extension, the Young Adult Psychiatric Assessment (YAPA) 
thereafter.20, 21 These structured interviews were coded by a trained interviewer, and each 
interview was subsequently checked by a supervisor. A detailed glossary provides the 
operational rules for each item assessed. In addition to the cannabis-related variables 
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described below, the interview collected information on sex, race/ethnicity, and variables 
needed to calculate poverty status according to the federal guidelines for the year in which 
the assessment took place.
Cannabis Involvement—For the current analysis, the focus was on cannabis 
involvement, including DSM-5 CUD, DSM-IV abuse, DSM-IV dependence, and non-
diagnostic frequency measures for daily, weekly, or any cannabis use. The substance use 
module of the CAPA/YAPA assesses cannabis use, abuse, addiction, and disorder. The 
phenomenology of cannabis use was assessed via age-of-onset, frequency of use, symptoms 
of DSM-IV abuse and dependence, DSM-5 CUD, and associated features of problematic 
use. These include: use of cannabis to improve mood, narrowed substance use repertoire, use 
first thing in the morning, blackouts, and cannabis-related criminality. Although DSM-5 
CUD symptoms of craving and withdrawal were not part of DSM-IV abuse or dependence 
diagnostic criteria, these data have been collected since the start of the GSMS study in 1993. 
The time frame for determining the presence of diagnostic items (both DSM-IV and DSM-5) 
was the three months immediately prior to the interview to minimize recall biases. 
Assessment of cannabis use and frequency of use included assessments of three-month 
primary periods for each interview, cumulatively across all interviews (i.e., across 8, 10, and 
11 interviews for the oldest, middle, and youngest cohorts, respectively), and an ever/
lifetime status.
The structure of the CAPA/YAPA substance use section consists of a preliminary section 
covering the use of specific substances, followed by a detailed section on symptoms and 
impairment, asked only if use is reported. Scoring algorithms written in SAS generate 
variables indicative of symptoms for DSM-IV abuse and dependence diagnoses and DSM-5 
CUD. In a two-week test retest study to determine the reliability of participant reporting, the 
intraclass correlation coefficient (ICC) for the number of substance abuse/dependence 
symptoms was .98.22
Analytic Strategy
Sampling weights were applied to account for differential probability of selection and to 
ensure that the results represent unbiased estimates for the original population from which 
the sample was drawn. All reported prevalence estimates are weighted, and all sample sizes 
are unweighted. In addition, sandwich-type variance corrections23 were applied to adjust for 
the parameter and variance effects induced by the sampling stratification. Weighted 
regression analyses were completed using PROC GENMOD in SAS 9.4.24
RESULTS
3-Month Point Prevalence of Cannabis Involvement
Figures 1A–E show age-related patterns from ages 9 to 30 for 3-month cannabis-related 
disorders and daily, weekly, and any cannabis use for non-Indian and Indian females and 
males. These figures illustrate rapid increases from preadolescence to late adolescence, 
peaking at ages 19–21, and subsequent declines in the mid-20s that remain stable (i.e., 
slower declines or no change) to age 30. These age-related prevalence patterns were 
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consistent with a cubic age effect for all frequency levels of cannabis involvement. The 
percentage of participants meeting DSM-5 CUD criteria (Figure 1a) was similar to that of 
participants meeting either DSM-IV cannabis abuse or dependence disorders (Figure 1b) and 
slightly higher than that of participants reporting daily use in a three-month primary period 
(Figure 1c) from 9–30 years old.
An approximate 2-to-1 sex ratio was observed across all frequency levels of cannabis 
involvement during peak use periods at 19–21 years. For example, daily use (Figure 1c) 
peaked at approximately 10–15% for males and up to 5% for females. Weekly use (Figure 
1d) peaked near 20% for males and just below 10% for females. Finally, any use in the past 
three months (Figure 1e) peaked at over 30% for males and over 15% for females. There 
was some evidence that the observed age-related patterns differed by sex and age by sex 
interactions in the trend range (p<.10). Among females only, the cubic age effect was 
significant (p<.05) for DSM-5 CUD, DSM-IV abuse/dependence, weekly use, and any use, 
while daily use showed no age-related effect.
There were no consistent significant differences in overall levels or developmental trends of 
cannabis involvement by Indian/non-Indian status. Only at very specific ages did American 
Indians report slightly higher cannabis involvement (ps < .05). For instance, at age 19, 
American Indian males had the highest any use, weekly use, daily use, and DSM-5 CUD, 
and at ages 13–14 American Indian females reported the most any use and DSM-IV 
cannabis abuse/dependence. In turn, at age 30, American Indian females had the lowest 
levels of involvement for weekly and any cannabis use.
Cumulative Prevalence Across Childhood and Early Adulthood
Given the potentially harmful effects of cannabis exposure during the first few decades of 
life, an important public health question is just how many participants have reported 
cannabis involvement cumulatively—at some point from childhood to early adulthood. By 
age 30, 18% of study participants had met criteria for DSM-5 CUD and 21% for DSM-IV 
cannabis abuse/dependence (Table 1). Males had higher cumulative prevalence estimates 
than females for both DSM-IV and DSM-5 disorders. Race/ethnic differences in cumulative 
diagnostic prevalence estimates did not emerge. When the ever/lifetime variables were 
aggregated into cumulative lifetime prevalence variables, the data indicated that by age 30, 
one in three participants had used cannabis daily at some point; almost half had a period of 
weekly use; and over 7 in 10 participants had used cannabis (i.e., any use). Overlaying the 
cumulative ever/lifetime involvement data and cumulative diagnostic data suggested that 
25% of participants who reported ever using cannabis met criteria for DSM-5 CUD.
Males reported more frequent involvement than females across all use variables (e.g., daily, 
weekly) except any use. With respect to race/ethnic differences, American Indians reported 
more cumulative and ever/lifetime “daily use” and also more ever/lifetime “weekly use” but 
not cumulative “any use” or “ever weekly use.” Table S1, available online, provides 
cumulative prevalence estimates for all categories of cannabis involvement up to age 16 
when high levels of involvement were much less common.
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Ages-of-Onset
Median ages-of-onset were derived from the ever/lifetime variables (except for DSM 
diagnoses, which were assessed using the three-month time frame only). The median age-of-
onset for cannabis-related disorders was around age 19 (Table 2; Figure S1, available 
online). For the non-diagnostic use variables, at least one in four users initiated use by age 
16 or earlier according to interquartile ranges. Significant sex differences existed for both the 
diagnostic and non-diagnostic variables, with males typically displaying earlier onsets than 
females. Race/ethnic differences did not emerge for the diagnostic age-of-onset data, but 
they did emerge for all frequency of use data, with American Indians typically initiating use 
at earlier ages than non- Indians (noted higher cumulative rates by age 16 in Table S1, 
available online).
Age-of-onset data was also used to understand progression to high-frequency use. These 
analyses revealed that those who met criteria for DSM-5 CUD initiated cannabis use earlier 
than those who never met full CUD criteria (median of 13.3 vs. 15.5 years, p <.001). 
Similarly, youth who reported daily use at some point by age 30 had a significantly younger 
age-of-onset of cannabis use compared to their peers who reported any use but never daily 
use (median of 14.0 vs. 16.3 years, p <.001).
DSM-5 and DSM-IV Overlap
Figure 2a shows the levels of co-occurrence for participants who met criteria for either 
DSM-5 CUD or DSM-IV cannabis disorder (abuse or dependence) at any given assessment 
and also cumulatively by age 30. The overlap was high and statistically significant (any 
given assessment: OR=52.0, 95% CI, 34.9–77.6, p <.001 or κ= 0.49; cumulatively: 
OR=19.2, 95% CI, 11.0–44.6, p <.001 or κ= 0.55). At any given wave, nearly half of the 
participants who met criteria for a cannabis disorder according to one of the DSM diagnostic 
guidelines failed to meet criteria for the other. Figure 2b shows the overlap between specific 
DSM-IV disorders and DSM- 5 CUD at any given wave. Overall, approximately a third of 
participants met criteria for a diagnosis of DSM-IV abuse/dependence, DSM-5 CUD, or 
both. The high overlap was primarily due to DSM-IV abuse, as there were no cases of DSM-
IV dependence that failed to meet criteria for DSM-5 CUD. This raises the question of who 
is meeting criteria for DSM-5 CUD but did not meet criteria for either DSM-IV disorder. 
Participants meeting criteria for DSM-5 CUD only reported no DSM-IV abuse symptoms 
(by definition) but did report a mean of 1.7 dependence symptoms (SD=0.54). (This 
compared to a mean of 2.1 symptoms [SD=0.87] for cases that overlapped.) Thus, in this 
sample, DSM-5 CUD identified subthreshold DSM-IV dependence cases with no abuse 
symptoms. These cases, also known as diagnostic orphans, were previously undiagnosed.
DSM-5 Cannabis Use Disorder and Frequent Cannabis Use
Finally, we examined overlap between DSM-5 CUD and frequent (i.e., daily) cannabis use. 
Figure 3a shows the levels of co-occurrence for those reporting either daily cannabis use or 
CUD at any given assessment and also cumulatively by age 30. The overlap was much 
greater than expected by chance (any given assessment: OR=151.0, 95% CI, 91.1–250.4, p 
<.001 or κ= 0.64; cumulatively: OR=95.3, 95% CI, 46.3–195.7, p <.001 or κ= 0.73). While 
DSM-5 CUD without daily use occurred some of the time, daily cannabis use without also 
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meeting criteria for CUD was very rare. Figure 3b shows the cumulative overlap by the 
number of individual assessments at which an individual met criteria for CUD or reported 
daily cannabis use. As expected, the more often an individual reported daily use, the more 
likely s/he was to also report DSM-5 CUD and vice versa. A comparison of those who met 
criteria for DSM-5 CUD but never reported using cannabis daily with those who reported 
CUD and daily use showed significant differences on 2 of the 11 symptoms of CUD: time 
spent obtaining/using/recovering and craving. Individuals who reported daily use and met 
CUD diagnosis had significantly higher endorsement levels for both symptoms than those 
with CUD only (time spent: 96.4% vs. 61.6%, p <.001; craving: 70.2% vs. 11.6%, p <.001).
DISCUSSION
Using the GSMS sample to assess participants from 9–30 years of age, we observed that 
levels of cannabis involvement were constantly changing, with steep increases across 
adolescence to a peak in early adulthood followed by decreases and subsequent plateaus to 
the early 30s. The findings are consistent with previous cross-sectional and shorter-term 
longitudinal studies of cannabis use.25–27 By age 30, approximately 70% of all participants 
had used cannabis at some point, over 30% had used cannabis daily, and 18% had met 
criteria for DSM-5 CUD based on cumulative prevalence estimates. This cumulative 
prevalence was higher than the National Epidemiologic Survey on Alcohol and Related 
Conditions (NESARC) III total lifetime estimate of 6.3% on average and 11% for ages 18–
29.28 NESARC’s lower estimate is likely due to the cross-sectional, single-wave design with 
retrospective lifetime reports. Such designs tend to significantly underestimate the 
prevalence of mental health and substance disorders (e.g.,29,30)
Moreover, the observed GSMS cumulative prevalence estimate of DSM-5 CUD by age 30 is 
likely to be an underestimate, too. Our study assessed CUD in the 3 months immediately 
preceding each interview. Consequently, the assessments covered at most approximately two 
years and 9 months (11 assessments × 3 months) of our participants’ lives spanning a 21-
year period. In addition, cannabis use had not been decriminalized or legalized in North 
Carolina during the study period, which may have resulted in under-reporting. Thus, the 
“true” prevalence of DSM-5 CUD by age 30 likely exceeds the observed 20%. This 
projection is also supported by our cumulative ever/lifetime variables for use that found that 
1 in 4 individuals who had ever used cannabis by age 30 (70% of sample) also met criteria 
for DSM-5 CUD.
DSM-5 Comparison to DSM-IV and Frequency of Use Measures
Consistent with previous studies conducted among adults, the prevalence of CUD did not 
change dramatically when comparing DSM-5 and DSM-IV diagnoses.31, 32 The overlap in 
cases was substantial but not complete, below 50% at any given assessment. Inconsistencies 
in diagnoses were attributable to the addition of criteria in DSM-5 but also to the new 
minimum diagnostic threshold that falls between that of DSM-IV abuse and dependence. 
Consequently, only a subset of participants with DSM-5 CUD would meet full criteria for 
DSM-IV dependence. And, many participants with DSM-IV abuse would fail to meet 
minimum criteria for DSM-5 CUD. Importantly, the new DSM-5 CUD criteria cover DSM-
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IV diagnostic orphans, participants who were subthreshold for dependence but did not 
display abuse symptoms.32 As such, the changes to the DSM appear to have met the 
intended goals of raising the minimum threshold for having a cannabis disorder and covering 
prior diagnostic orphans.
At the same time, it is noteworthy that the overlap of DSM-5 was greater with a simple 
measure of daily cannabis use than with the DSM-IV constructs. Combined with prior 
findings, this study supports inclusion of frequency of use measures to future DSM criteria 
for CUD.33 Finally, additional work must be done on how this revised DSM construct relates 
to other psychiatric disorders over time (i.e., which disorders or comorbidities best predict 
DSM-5 CUD and vice versa).
Sex and Race Differences in Cannabis Involvement
Our findings suggest that overall levels of cannabis use and disorder were higher in males 
than in females, as has been shown in other studies.12,14–16 It is important to note, however, 
that the overall age-related pattern of steep increases in adolescence, peaks in young 
adulthood, and decreases/plateaus to age 30 did not differ by sex, suggesting similar 
developmental patterns despite underlying sex differences in overall levels.
There were no consistent race/ethnic differences in the point prevalence of 3-month use, 
DSM disorders, or the overall age-related trends in cannabis use. (The exceptions, Indian 
females in early adolescence and Indian males at age 19, were observed early in 
development.) The lack of race/ethnic differences is noteworthy because American Indians 
were exposed to substantially higher rates of poverty in our sample, and this risk factor is 
typically linked to substance use and disorders.5, 6 Resilience in our American Indian study 
population has been reported previously (to ages 19 and 21) and is, in part, attributable to 
income supplements received by American Indian families and their community following 
casino openings in the late 1990s.34 These findings are also consistent with correlational 
studies reporting that differences in substance use between American Indian and white 
participants are no longer significant when adjusting for annual family income and education 
level (and also sex, age, urbanicity, and region).26 There may be additional explanations for 
the late adolescent declines in use. Whitebeck et al. reported similar declines in late 
adolescents’ substance use in an indigenous sample that did not experience an income 
shock.35 As in their study, it is possible that cultural changes to promote greater resilience 
within the tribe could have contributed to the decline in cannabis use in late adolescence.
However, by age 30, our study identified higher cumulative ever/lifetime estimates in weekly 
and daily use among American Indians. These differences were likely due to an earlier age-
of-onset of cannabis use among American Indian youth compared to their non-Indian 
neighbors. For example, by age 16, 38% of American Indian females and 28% of American 
Indian males had reported lifetime use compared to 15% and 23% of non-Indian females 
and males, respectively. High prevalence and “reverse” sex differences in early cannabis use 
would be consistent with previous work on American Indians.36, 37 Early onset and frequent 
use often predict subsequent problematic use,38 thus our lack of race/ethnic differences in 3-
month use and CUD across ages is especially notable. Previous studies have reported faster 
increases in cannabis use among American Indians, which we did not find.7, 8 The 
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geographic integration and social, educational, and economic opportunities available to 
American Indian adolescents in our study could have shielded them from an escalation of 
use.
The prospective, longitudinal cohort design is both a strength and a weakness. On the one 
hand, this design allowed us to examine age-related changes in the prevalence of cannabis 
disorder and frequency of use in the same group of individuals over time. On the other hand, 
policies and attitudes toward cannabis use have changed dramatically from 1993 to 2015, as 
did the chemical composition of cannabis products used across this period. Consequently, 
the age- related changes observed here may not generalize to other historical times, cohorts, 
and places. Nevertheless, our overall prevalence estimates (e.g., of DSM-IV diagnostic 
constructs) were remarkably similar to those from other studies from around the globe. In 
addition, the sample is only representative of the community from which it was drawn. 
Consequently, it is not representative of the US population in that American Indians are 
overrepresented and African Americans and Latinos underrepresented. It is also important to 
note that the Indian tribe studied here is distinctive in terms of its history and economics and 
social circumstances, and our findings are not meant to be representative of other tribes. 
Nevertheless, heterogeneity among Indian tribes should not be a barrier to research on this 
disadvantaged group, and our findings may inform expectations for other groups with 
similar characteristics.
This analysis has implications for a research agenda for DSM-5 CUD. First, given that close 
to 1 in 5 individuals met criteria for this disorder by age 30 and 1 in 3 reported daily use, it is 
imperative for additional work to test causal links between early life course cannabis 
involvement and later morbidities. This would prioritize longitudinal studies with detailed 
baseline data (particularly health measures) and adequate controls (e.g., sibling analysis, 
twin designs) as well as natural experiments that capitalize on the differences in legal 
restrictions regarding cannabis use across states and countries. Second, our age-related 
findings suggest that a joint consideration of late adolescence (as the period of highest first 
use) and the late 20s (as a key period of potential desistance from use) should be a priority 
for cannabis use researchers. A shift to analyses of developmental trajectories of age-at-
initiation, duration of use, and desistance from use could be especially beneficial to 
understand precursors, correlates, and outcomes. Future studies of early risk factors for 
cannabis involvement should take into account these developmental findings to better 
understand what predicts cannabis use that persists into adulthood.
Our findings suggest that DSM-5 CUD is an improvement over DSM-IV diagnostic 
constructs by both raising the threshold for diagnosis and including important additional 
criteria while also eliminating some DSM-IV diagnostic orphans. Our findings also indicate 
that a simple heuristic for clinicians to assess risk for DSM-5 CUD is to ask about frequency 
of use. If daily use is reported, then DSM-5 CUD is likely.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Three-month prevalence estimates for a) DSM-5 cannabis use disorder (CUD), b) DSM-IV 
abuse or dependence, c) daily cannabis use, d) weekly cannabis use, and e) any cannabis use 
from ages 9 to 30 by sex and Indian/non-Indian status.
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Figure 2. 
Co-occurrence of DSM-5 cannabis disorder a) with DSM-IV status at any given assessment 
and cumulatively and b) with specific DSM-IV cannabis disorder at a given assessment.
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Figure 3. 
Co-occurrence of DSM-5 cannabis use disorder a) and daily cannabis use at any given 
assessment and cumulatively and b) with daily cannabis use cumulatively by the number of 
assessments with reported disorder or daily use.
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